tiprankstipranks
Shield Therapeutics PLC (DE:1JS)
FRANKFURT:1JS
Germany Market
1JS
Shield Therapeutics
RESEARCH TOOLSreports

Shield Therapeutics (1JS) Income Statement

2 Followers

Shield Therapeutics Income Statement

Last quarter (Q2 2026), Shield Therapeutics's total revenue was £30.12M, an increase of 148.11% from the same quarter last year. In Q2, Shield Therapeutics's net income was £-2.23M. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Dec 24Dec 23Dec 22Jun 22
Total Revenue
$ 50.74M$ 32.18M$ 16.54M£ 4.48M£ 1.52M
Gross Profit
$ 22.38M$ 13.22M$ 5.09M£ 2.00M£ -1.67M
Operating Expenses
$ 32.68M$ 37.80M$ 44.69M£ 52.21M£ 18.74M
Depreciation and Amortization
$ 1.14M$ 1.43M$ 1.35M£ 2.87M£ 2.21M
EBITDA
$ -9.16M$ -21.26M$ -38.28M£ -46.07M£ -17.69M
Operating Income
$ -10.30M$ -22.87M$ -31.33M£ -26.39M£ -20.41M
Other Income/Expenses
$ -7.20M$ -3.68M$ -1.04M£ -13.67M£ 498.00K
Pretax Income
$ -17.50M$ -26.56M$ -32.38M£ -40.08M£ -19.91M
Net Income
$ -18.03M$ -26.61M$ -33.29M£ -40.44M£ -19.34M
Per Share Metrics
Basic EPS
$ -0.02$ -0.03$ -0.05£ -0.17£ -0.09
Diluted EPS
$ -0.02$ -0.03$ -0.05£ -0.17£ -0.09
Weighted Average Shares Outstanding
 881.34M 905.20M 722.54M 233.19M 204.41M
Weighted Average Shares Outstanding (Diluted)
 881.34M 905.20M 722.54M 233.19M 204.41M

Shield Therapeutics Earnings and Revenue History